I generally look at analyst ratings with a subjective eye, as many pan out and many don't pan out. Stifel Nicolaus re-affirmed its rating on Google common shares last Friday with a $500 target share price. While I can see the reason for being behind and continuing to support a buy rating on Google, I do think that the $500 price target is a bit much. Ok, way, way too much. Strange thing is, GOOG shares will probably get there.
Google's saving grace for revenue at this time is auctioning text advertising space next to the billions of Internet searches Google customers perform each month. Yes, it's released a pretty incredible stream of products recently, as it launches early and often. But, not enough time has passed for the success of many of these Google products to be shown -- if they will be successful. Google Finance, Google Calendar, Google Checkout are all recent web product releases that have excellent potential. The question of the hour is how Google plans on making money on any of these services.
Yes, Google can ride on the wave of revenue it's currently enjoying with Internet search advertising. That has enabled the Google folks to hoard back a pretty decent amount of cash. But, its burn rate could increase (take a look at this data center in Oregon) based on the product trajectory it has and will have, and its diversification of revenue most likely needs to expand at the same time, for sanity's sake. So, at a $500 per share price target, what's the justification? Bubbles?
Last updated: February 10, 2012: 02:47 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
TheFlyOnTheWall.com Headlines
- Market lower, moving in narrow range
- MSCI Italy Index volatility increases on S&P downgrade of Italy-based banks
- Mattel sees no material impact in 2012 from HiT acquisition
- Apple reverses lower, support is at $488.55
- Mattel targets 2012 year end cash $800M-$1B
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Savings Experiment: Snow Removal
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?

